Interesting I did not know about IXC repurposing exenatide. I don't think something like ozempic will "obliterate" DXB's drug but it's pretty obvious seeing the landscape that diabetes drugs like SGLT2 inhibitors, finerenone and GLP1 drugs such as ozempic are spreading quickly into kidney diseases of all types. The kidney guidelines now recommend SGLT2 inhibitors for any CKD patient with proteinuria which will cover FSGS. The SGLT2 class is also anti inflammatory as shown in this paper, it even targets CCR2 and other inflammatory markers so it doing what DXB's drug does, and offers more. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485634/
DXB Price at posting:
38.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)